Nitrosamine Assessment
Syngene offers comprehensive nitrosamine evaluation through mutagenicity testing, including Enhanced Ames, HPRT, and TK6 assays along with carcinogenic potency categorization (CPCA) to support regulatory‑compliant impurity risk assessment.
Batch Manufacturing vs Continuous Manufacturing with Process Analytical Technology
Batch vs continuous manufacturing explained, how process analytical technology enables control and real-time release testing, and when each mode fits best.
The Critical Role of Analytical Development: Supporting a Program with 70+ Method Validations
See how analytical development scales to 70 plus method validations with phase appropriate, risk based strategy and clean execution. Read the full guide today.
Urban Mental Health: Evidence, Action, and Impact through BUMHI
Explore how the BUMHI initiative advances urban mental health through research, evidence-based action, and community impact to build healthier cities.
Cost of Goods Reduction by Design: Strategies for Early-Phase Process Optimization
Reduce CoG by using design of experiments, quality by design, and smart tech transfer in early development. Practical strategies to cut cost without risk.
From Patient Tumors to Predictive Models
Syngene builds patient‑derived organoids and xenograft models that preserve tumor biology, enabling high‑throughput screening and in vivo validation to improve predictive accuracy and drive confident translational decision‑making.
Computational toxicology – The new frontier in predictive safety assessment
Peptide synthesis and the hidden complexities of scaling peptide therapeutics, from SPPS to purification, analytics, and cGMP manufacturing. Talk to our team today.
Project Optimus – Transforming the paradigm of dose optimization and selection in oncology
Discover how Project Optimus is changing oncology drug development through data-driven dose optimization and modeling strategies. Learn more today.
Peptide synthesis and the hidden complexities of scaling peptide therapeutics
Peptide synthesis and the hidden complexities of scaling peptide therapeutics, from SPPS to purification, analytics, and cGMP manufacturing. Talk to our team today.
Hybrid, device-enabled IPF cough trial for a Swedish sponsor— integrated formulation-to-site execution by Syngene
In this case study, you would learn how Syngene enabled a hybrid, device-based IPF cough trial in India for a clinical-stage pharma company—delivering seamless formulation-to-site execution with robust data integrity, regulatory navigation, and on-time delivery.